Immunotherapeutic strategies in kidney cancer--when TKIs are not enough

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Metastatic clear-cell renal-cell carcinoma (CC-RCC) management has been transformed by targeted therapies.
• Approved agents include multitargeted tyrosine kinase inhibitors (TKIs) and mTOR inhibitors.
• However, these therapies often fail to achieve durable complete responses, limiting their clinical utility.

Purpose of the Study:

• To emphasize the importance of immunobiology in CC-RCC.
• To propose improved patient selection for interleukin 2 therapy.
• To facilitate the development of novel immunotherapeutic strategies for advanced CC-RCC.

Main Methods:

• Review of current literature on targeted therapies and immunobiology in CC-RCC.
• Analysis of the limitations of existing targeted treatments.
• Conceptual framework for integrating immunotherapy into CC-RCC management.

Main Results:

• Targeted therapies (sunitinib, sorafenib, temsirolimus) have improved CC-RCC treatment but lack durable responses.
• Immunotherapeutic approaches, though historically considered, hold potential for advanced CC-RCC.
• Understanding CC-RCC immunobiology is crucial for optimizing immunotherapy.

Conclusions:

• Immunotherapy remains a vital component in managing advanced CC-RCC, even with targeted therapies.
• Further research into CC-RCC immunobiology can enhance patient selection for immunotherapy.
• Novel immunotherapeutic strategies are needed to overcome limitations of current treatments.